GHRP-6

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide and the first clinically studied growth hormone secretagogue, developed in the late 1970s and 1980s as part of groundbreaking research into the regulation of GH secretion. It was the molecule that established the existence of the GHS-R receptor system - later found to be the same receptor activated by the endogenous hormone ghrelin, which was only discovered in 1999, decades after GHRP-6 research began.

The peptide functions by binding GHS-R1a receptors in both the pituitary and hypothalamus, directly stimulating somatotroph cells to release stored GH while also suppressing somatostatin activity. This dual central mechanism produces potent, reproducible GH pulses that peak within 15-30 minutes of subcutaneous administration. Unlike exogenous growth hormone (rhGH), GHRP-6 preserves the pulsatile pattern of GH release - a physiologically important distinction since the pulse pattern is a key determinant of GH's tissue-specific effects.

Perhaps the most distinctive feature of GHRP-6 is its profound appetite stimulation. As a ghrelin mimetic, it activates orexigenic pathways in the hypothalamus that increase appetite and food-seeking behaviour. This effect is stronger with GHRP-6 than with GHRP-2 or Ipamorelin, making it particularly valuable in research models of cachexia (wasting syndrome), anorexia, and sarcopenia where increasing caloric intake is a research objective.

Beyond GH secretion, the last two decades of GHRP-6 research have uncovered an extensive range of tissue-protective effects that appear to operate through peripheral GHS-R1a receptors independently of pituitary GH release. Cardioprotective studies have shown GHRP-6 significantly reduces infarct size in models of myocardial ischaemia-reperfusion injury. Hepatoprotective research has demonstrated reductions in liver fibrosis biomarkers and protection against CCl4-induced hepatotoxicity. Neurological studies have documented neuroprotection in models of excitotoxicity and cerebral ischaemia.

Anti-inflammatory properties have been extensively characterised in both in vitro and in vivo models. GHRP-6 reduces production of pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6, while upregulating anti-inflammatory mediators. This makes it relevant to research in inflammatory bowel disease, rheumatoid arthritis, and metabolic inflammation models.

GHRP-6 is typically compared to its successor GHRP-2, which offers similar GH-releasing potency with reduced cortisol/prolactin elevation. Researchers who specifically require the appetite-stimulating component or the particular peripheral tissue effects of GHRP-6 still prefer it for those applications. Combined with a GHRH analogue, GHRP-6 produces synergistic GH elevation that far exceeds either peptide alone.